ReviewNucleic acid therapeutics2023
DNAzymes: Expanding the Potential of Nucleic Acid Therapeutics.
Review in Nucleic acid therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Review
- A Zeolitic Pyrimidine Framework (ZPF) Nanoplatform Co-Delivers a DNAzyme and a Protein Prodrug for Cascade-Activated Tumour Therapy.Cell proliferation · 2026Article
- The 10-23 DNAzyme in Biosensing and Diagnostics: Applications, Challenges, and Future Directions.Angewandte Chemie (International ed. in English) · 2026Review
- Advances in DNAzyme Selection, Molecular Engineering and Biomedical Applications.International journal of molecular sciences · 2026Review
- Metal surface-triggered DNAzyme catalysis for efficient DNA cleavage.Communications chemistry · 2026Article
- A modified X10-23 DNAzyme that can better access large, structured RNA targets.Nucleic acids research · 2026Article
- The efficacy of oligonucleotide-based gene therapeutics in gene silencing.Theranostics · 2026Review
- Ginger-Derived Nanoparticles Deliver a VEGFA-Targeting DNAzyme and Modulate Retinal VEGFA Expression and Inflammatory Markers in Experimental Diabetic Retinopathy.International journal of nanomedicine · 2026Article
- GATA-Biology · 2025Article
- Synzymes: The Future of Modern Enzyme Engineering.Applied biochemistry and biotechnology · 2025Review
- Novel In Vitro Selection ofCells · 2025Article
- Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges.Journal of nanobiotechnology · 2025Review
- Influence of LNA modifications on the activity of the 10-23 DNAzyme.RSC advances · 2025Article
- Opening new frontiers with catalytic nucleic acids in miRNA inhibition.Frontiers in pharmacology · 2025Review
- Multivalent DNAzyme agents for cleaving folded RNA.Nucleic acids research · 2024Article
- Interplay of graphene-DNA interactions: Unveiling sensing potential of graphene materials.Applied physics reviews · 2024Article
- NucleoCraft: The Art of Stimuli-Responsive Precision in DNA and RNA Bioengineering.BME frontiers · 2024Review
- Systematic Analysis of 2'-Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acids drugs have been proven in the clinic as a powerful modality to treat inherited and acquired diseases. However, key challenges including drug stability, renal clearance, cellular uptake, and movement across biological barriers (foremost the blood-brain barrier) limit the translation and clinical efficacy of nucleic acid-based therapies, both systemically and in the central nervous system. In this study we provide an overview of an emerging class of nucleic acid therapeutic, called DNAzymes. In particular, we review the use of chemical modifications and carrier molecules for the stabilization and/or delivery of DNAzymes in cell and animal models. Although this review focuses on DNAzymes, the strategies described are broadly applicable to most nucleic acid technologies. This review should serve as a general guide for selecting chemical modifications to improve the therapeutic performance of DNAzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.